ATRC vs. OFIX, ATEC, SRDX, INO, IART, MDXG, NVCR, AORT, FNA, and LMAT
Should you be buying AtriCure stock or one of its competitors? The main competitors of AtriCure include Orthofix Medical (OFIX), Alphatec (ATEC), Surmodics (SRDX), Inovio Pharmaceuticals (INO), Integra LifeSciences (IART), MiMedx Group (MDXG), NovoCure (NVCR), Artivion (AORT), Paragon 28 (FNA), and LeMaitre Vascular (LMAT). These companies are all part of the "surgical & medical instruments" industry.
AtriCure (NASDAQ:ATRC) and Orthofix Medical (NASDAQ:OFIX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings.
AtriCure presently has a consensus target price of $52.63, indicating a potential upside of 128.31%. Orthofix Medical has a consensus target price of $15.50, indicating a potential upside of 14.31%. Given AtriCure's stronger consensus rating and higher possible upside, equities research analysts plainly believe AtriCure is more favorable than Orthofix Medical.
AtriCure has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Orthofix Medical has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500.
99.1% of AtriCure shares are owned by institutional investors. Comparatively, 89.8% of Orthofix Medical shares are owned by institutional investors. 3.2% of AtriCure shares are owned by insiders. Comparatively, 4.7% of Orthofix Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, AtriCure had 6 more articles in the media than Orthofix Medical. MarketBeat recorded 13 mentions for AtriCure and 7 mentions for Orthofix Medical. AtriCure's average media sentiment score of 0.32 beat Orthofix Medical's score of 0.15 indicating that AtriCure is being referred to more favorably in the media.
AtriCure has a net margin of -7.62% compared to Orthofix Medical's net margin of -20.28%. AtriCure's return on equity of -7.55% beat Orthofix Medical's return on equity.
AtriCure received 135 more outperform votes than Orthofix Medical when rated by MarketBeat users. Likewise, 68.86% of users gave AtriCure an outperform vote while only 61.78% of users gave Orthofix Medical an outperform vote.
AtriCure has higher earnings, but lower revenue than Orthofix Medical. AtriCure is trading at a lower price-to-earnings ratio than Orthofix Medical, indicating that it is currently the more affordable of the two stocks.
Summary
AtriCure beats Orthofix Medical on 15 of the 18 factors compared between the two stocks.
Get AtriCure News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AtriCure Competitors List
Related Companies and Tools
